KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Common Equity (2017 - 2026)

Elanco Animal Health's Common Equity history spans 9 years, with the latest figure at $6.5 billion for Q4 2025.

  • On a quarterly basis, Common Equity rose 7.4% to $6.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.5 billion, a 7.4% increase, with the full-year FY2025 number at $6.5 billion, up 7.4% from a year prior.
  • Common Equity hit $6.5 billion in Q4 2025 for Elanco Animal Health, down from $6.7 billion in the prior quarter.
  • Over the last five years, Common Equity for ELAN hit a ceiling of $8.0 billion in Q1 2021 and a floor of $5.9 billion in Q2 2024.
  • Historically, Common Equity has averaged $6.9 billion across 5 years, with a median of $6.8 billion in 2025.
  • Biggest five-year swings in Common Equity: increased 20.21% in 2021 and later fell 19.92% in 2024.
  • Tracing ELAN's Common Equity over 5 years: stood at $7.5 billion in 2021, then dropped by 2.92% to $7.3 billion in 2022, then decreased by 14.62% to $6.2 billion in 2023, then decreased by 2.04% to $6.1 billion in 2024, then grew by 7.4% to $6.5 billion in 2025.
  • Business Quant data shows Common Equity for ELAN at $6.5 billion in Q4 2025, $6.7 billion in Q3 2025, and $6.8 billion in Q2 2025.